Disease-associated RNA and protein signatures in iPSC-derived microglia model of Alzheimer's disease

Wenzhe Wu1, Eun Seok Choi1, Luke Liu2,3

  • 1Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, United States.

Abstract

Insights

Induced pluripotent stem cell-derived microglia from Alzheimer's disease (AD) patients reveal significant molecular changes. These findings highlight novel small non-coding RNAs and pathways involved in microglial dysfunction, offering potential therapeutic targets for AD.

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Microglia are crucial for brain homeostasis and inflammation.
  • Microglial dysfunction is implicated in Alzheimer's disease (AD) pathogenesis.
  • Molecular mechanisms of microglial alterations in AD are not fully understood.

Purpose of the Study:

  • To characterize disease-associated molecular changes in microglia derived from induced pluripotent stem cells (iPSCs) of sporadic AD patients.
  • To investigate alterations in mRNA, protein, and small non-coding RNA (sncRNA) expression in AD microglia.
  • To identify novel sncRNAs and pathways involved in AD-related microglial dysfunction.

Main Methods:

  • Generated iPSC-derived microglia from sporadic AD patients and healthy controls.
  • Employed integrated multi-omics approaches: total RNA sequencing, proteomics, and sncRNA sequencing.
  • Utilized a modified T4 polynucleotide kinase (T4 PNK)-based method for sncRNA profiling.

Main Results:

  • Identified significant AD-associated alterations in mRNA, protein, and sncRNA profiles in iPSC-derived microglia.
  • Gene Ontology analysis revealed dysregulated pathways in extracellular communication, intracellular transport, cytoskeletal organization, and protein interactions.
  • Discovered multiple disease-associated sncRNAs, including novel RNA species potentially linked to AD pathology.

Conclusions:

  • iPSC-derived microglia serve as a valuable model for studying sporadic AD molecular mechanisms.
  • Identified molecular alterations highlight pathways in microglial dysfunction and neurodegeneration.
  • Novel disease-associated sncRNAs may offer new insights into AD pathogenesis and therapeutic targets.